Cresco Labs Inc. (CRLBF) Posts Q3 Loss but Exceeds Revenue Projections
Cresco Labs Quarterly Performance: Cresco Labs Inc. reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of a loss of $0.03, and showing a decline in revenue to $164.91 million compared to $179.78 million a year ago.
Earnings Outlook and Stock Rating: The company's earnings outlook is currently unfavorable, resulting in a Zacks Rank #4 (Sell), indicating expected underperformance in the near future, with consensus estimates for the upcoming quarter at -$0.03 EPS on $163.65 million in revenues.
Market Comparison: Cresco Labs shares have increased by about 9.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 14.3%, raising concerns about future stock performance.
Industry Context: The Medical - Products industry, to which Cresco Labs belongs, is currently ranked in the bottom 35% of Zacks industries, suggesting that the overall industry outlook could significantly impact the stock's performance.
Trade with 70% Backtested Accuracy
Analyst Views on FTLF
About FTLF
About the author
FitLife Brands Indicates Continued Margin Strain and Weak Consumer Demand After Acquiring Irwin Naturals
Management Overview: FitLife Brands reported a 47% year-over-year revenue increase to $23.5 million in Q3 2025, largely driven by the acquisition of Irwin Naturals, which contributed $6.8 million in revenue during the quarter. However, gross margin declined to 37.2% from 43.8% due to increased costs and integration challenges.
Financial Performance: The company experienced a drop in net income to $0.9 million from $2.1 million in the previous year, attributed to merger-related expenses and lower gross margins. MusclePharm showed strong organic growth of 55%, while MRC faced ongoing headwinds.
Consumer Trends and Challenges: Management noted signs of consumer weakness, including declining Amazon subscriber counts and reduced wholesale orders. They anticipate continued cost pressures, particularly from rising whey protein prices, and plan to implement price increases for MusclePharm products.
Outlook and Strategic Focus: FitLife Brands aims to optimize margins and manage operational complexities while navigating a challenging macro environment. The company is shifting Irwin's sales strategy towards online channels, which may introduce execution risks but is expected to enhance revenue over time.
Cresco Labs Inc. (CRLBF) Posts Q3 Loss but Exceeds Revenue Projections
Cresco Labs Quarterly Performance: Cresco Labs Inc. reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of a loss of $0.03, and showing a decline in revenue to $164.91 million compared to $179.78 million a year ago.
Earnings Outlook and Stock Rating: The company's earnings outlook is currently unfavorable, resulting in a Zacks Rank #4 (Sell), indicating expected underperformance in the near future, with consensus estimates for the upcoming quarter at -$0.03 EPS on $163.65 million in revenues.
Market Comparison: Cresco Labs shares have increased by about 9.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 14.3%, raising concerns about future stock performance.
Industry Context: The Medical - Products industry, to which Cresco Labs belongs, is currently ranked in the bottom 35% of Zacks industries, suggesting that the overall industry outlook could significantly impact the stock's performance.
Daily Upgrade Report for Validea's Joel Greenblatt Strategy - October 18, 2025
Validea's Earnings Yield Investor Model: The model, based on Joel Greenblatt's strategy, upgraded FitLife Brands Inc. (FTLF) from a 70% to an 80% rating, indicating increased interest due to strong fundamentals and valuation.
Company Overview: FitLife Brands, Inc. specializes in developing and marketing nutritional supplements and wellness products, offering around 250 products through various online and retail channels, including brands like NDS Nutrition and MusclePharm.
Daily Upgrade Report for Validea's Joel Greenblatt Strategy - September 3, 2025
Validea's Earnings Yield Investor Model: The model, based on Joel Greenblatt's strategy, identifies companies with high return on capital and earnings yields, highlighting Nathan's Famous Inc. and AutoNation Inc. as stocks with increased ratings from 80% to 90% due to strong fundamentals and valuations.
Company Profiles: Nathan's Famous Inc. operates in the restaurant industry, focusing on hot dog products, while AutoNation Inc. is an automotive retailer with various segments selling new and used vehicles, parts, and financing services.
FitLife Brands Inc. Rating Update: FitLife Brands, a small-cap growth stock in the Biotechnology & Drugs sector, saw its rating rise from 70% to 80%, indicating growing interest based on its fundamentals and valuation.
About Joel Greenblatt and Validea: Greenblatt's "Magic Formula" investment strategy has historically outperformed the market, and Validea provides stock analysis based on the strategies of renowned investors, aiming to help investors achieve long-term success.
Roth Capital Maintains Buy on FitLife Brands, Raises Price Target to $25
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript
Q2 2025 Financial Performance: FitLife Brands reported a 5% decline in total revenue year-over-year, totaling $16.1 million, with online sales contributing 65%. Gross profit and net income also decreased, primarily due to merger-related expenses from the acquisition of Irwin Naturals.
Management Commentary: CEO Dayton Judd opened the earnings call, highlighting the company's financial challenges and indicating that further details would be provided during the Q&A session.
FitLife Brands Indicates Continued Margin Strain and Weak Consumer Demand After Acquiring Irwin Naturals
Management Overview: FitLife Brands reported a 47% year-over-year revenue increase to $23.5 million in Q3 2025, largely driven by the acquisition of Irwin Naturals, which contributed $6.8 million in revenue during the quarter. However, gross margin declined to 37.2% from 43.8% due to increased costs and integration challenges.
Financial Performance: The company experienced a drop in net income to $0.9 million from $2.1 million in the previous year, attributed to merger-related expenses and lower gross margins. MusclePharm showed strong organic growth of 55%, while MRC faced ongoing headwinds.
Consumer Trends and Challenges: Management noted signs of consumer weakness, including declining Amazon subscriber counts and reduced wholesale orders. They anticipate continued cost pressures, particularly from rising whey protein prices, and plan to implement price increases for MusclePharm products.
Outlook and Strategic Focus: FitLife Brands aims to optimize margins and manage operational complexities while navigating a challenging macro environment. The company is shifting Irwin's sales strategy towards online channels, which may introduce execution risks but is expected to enhance revenue over time.
Cresco Labs Inc. (CRLBF) Posts Q3 Loss but Exceeds Revenue Projections
Cresco Labs Quarterly Performance: Cresco Labs Inc. reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of a loss of $0.03, and showing a decline in revenue to $164.91 million compared to $179.78 million a year ago.
Earnings Outlook and Stock Rating: The company's earnings outlook is currently unfavorable, resulting in a Zacks Rank #4 (Sell), indicating expected underperformance in the near future, with consensus estimates for the upcoming quarter at -$0.03 EPS on $163.65 million in revenues.
Market Comparison: Cresco Labs shares have increased by about 9.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 14.3%, raising concerns about future stock performance.
Industry Context: The Medical - Products industry, to which Cresco Labs belongs, is currently ranked in the bottom 35% of Zacks industries, suggesting that the overall industry outlook could significantly impact the stock's performance.
Daily Upgrade Report for Validea's Joel Greenblatt Strategy - October 18, 2025
Validea's Earnings Yield Investor Model: The model, based on Joel Greenblatt's strategy, upgraded FitLife Brands Inc. (FTLF) from a 70% to an 80% rating, indicating increased interest due to strong fundamentals and valuation.
Company Overview: FitLife Brands, Inc. specializes in developing and marketing nutritional supplements and wellness products, offering around 250 products through various online and retail channels, including brands like NDS Nutrition and MusclePharm.
Daily Upgrade Report for Validea's Joel Greenblatt Strategy - September 3, 2025
Validea's Earnings Yield Investor Model: The model, based on Joel Greenblatt's strategy, identifies companies with high return on capital and earnings yields, highlighting Nathan's Famous Inc. and AutoNation Inc. as stocks with increased ratings from 80% to 90% due to strong fundamentals and valuations.
Company Profiles: Nathan's Famous Inc. operates in the restaurant industry, focusing on hot dog products, while AutoNation Inc. is an automotive retailer with various segments selling new and used vehicles, parts, and financing services.
FitLife Brands Inc. Rating Update: FitLife Brands, a small-cap growth stock in the Biotechnology & Drugs sector, saw its rating rise from 70% to 80%, indicating growing interest based on its fundamentals and valuation.
About Joel Greenblatt and Validea: Greenblatt's "Magic Formula" investment strategy has historically outperformed the market, and Validea provides stock analysis based on the strategies of renowned investors, aiming to help investors achieve long-term success.
Roth Capital Maintains Buy on FitLife Brands, Raises Price Target to $25
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript
Q2 2025 Financial Performance: FitLife Brands reported a 5% decline in total revenue year-over-year, totaling $16.1 million, with online sales contributing 65%. Gross profit and net income also decreased, primarily due to merger-related expenses from the acquisition of Irwin Naturals.
Management Commentary: CEO Dayton Judd opened the earnings call, highlighting the company's financial challenges and indicating that further details would be provided during the Q&A session.
